Literature DB >> 19815047

Co-engagement of alpha(4)beta(1) integrin (VLA-4) and CD4 or CD8 is necessary to induce maximal Erk1/2 phosphorylation and cytokine production in human T cells.

Tae Kon Kim1, Matthew J Billard, Eric D Wieder, Bradley W McIntyre, Krishna V Komanduri.   

Abstract

The alpha(4)beta(1) integrin VLA-4 (very-late activation antigen-4) and the lineage-specific CD4 and CD8 receptors have been proposed as putative co-stimulatory receptors on T cells. To assess the relative contribution of signaling through the TCR, CD28 and these accessory molecules, we activated human T cells using soluble antibodies recognizing all four of these T-cell receptor classes (CD3, CD28, CD4/CD8, and VLA-4), and we assessed the degree of activation using higher-order flow cytometry detecting intracellular Erk1/2 phosphorylation and production of IL-2 and IFN-gamma. We found that: (1) co-stimulation via CD4/CD8, in addition to CD28, is required for optimal T-cell activation; (2) VLA-4 binding consistently potentiates CD4(+) and CD8(+) T-cell activation; (3) augmentation of T-cell activation through VLA-4 binding is most pronounced following engagement of CD4/CD8. These results confirm that multiple signals, including VLA-4 engagement, are necessary for maximal T-cell activation beyond that induced via the TCR and CD28.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19815047      PMCID: PMC2795106          DOI: 10.1016/j.humimm.2009.09.360

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  26 in total

1.  Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.

Authors:  K V Komanduri; J Feinberg; R K Hutchins; R D Frame; D K Schmidt; M N Viswanathan; J P Lalezari; J M McCune
Journal:  J Infect Dis       Date:  2001-03-12       Impact factor: 5.226

2.  Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry.

Authors:  Omar D Perez; Garry P Nolan
Journal:  Nat Biotechnol       Date:  2002-02       Impact factor: 54.908

3.  IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells.

Authors:  SangKon Oh; Liyanage P Perera; Donald S Burke; Thomas A Waldmann; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

4.  Costimulation: building an immunological synapse.

Authors:  M L Dustin; A S Shaw
Journal:  Science       Date:  1999-01-29       Impact factor: 47.728

5.  Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells?

Authors:  T W Chang; P C Kung; S P Gingras; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

6.  Vaccines with enhanced costimulation maintain high avidity memory CTL.

Authors:  Sixun Yang; James W Hodge; Douglas W Grosenbach; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

7.  OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.

Authors:  J P Van Wauwe; J R De Mey; J G Goossens
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

8.  Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.

Authors:  J W Hodge; A N Rad; D W Grosenbach; H Sabzevari; A G Yafal; L Gritz; J Schlom
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

9.  CD45RA T-cell activation without proliferation by a partial agonist monoclonal antibody to beta1 integrin.

Authors:  Matthew J Billard; Bradley W McIntyre
Journal:  Immunol Cell Biol       Date:  2008-01-15       Impact factor: 5.126

10.  Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells.

Authors:  Evren Ozdemir; Lisa S St John; Geraldine Gillespie; Sarah Rowland-Jones; Richard E Champlin; Jeffrey J Molldrem; Krishna V Komanduri
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

View more
  6 in total

1.  Integrin Activation Controls Regulatory T Cell-Mediated Peripheral Tolerance.

Authors:  Jane E Klann; Stephanie H Kim; Kelly A Remedios; Zhaoren He; Patrick J Metz; Justine Lopez; Tiffani Tysl; Jocelyn G Olvera; Jailal N Ablack; Joseph M Cantor; Brigid S Boland; Gene Yeo; Ye Zheng; Li-Fan Lu; Jack D Bui; Mark H Ginsberg; Brian G Petrich; John T Chang
Journal:  J Immunol       Date:  2018-04-27       Impact factor: 5.422

Review 2.  Memory T cells in organ transplantation: progress and challenges.

Authors:  Jaclyn R Espinosa; Kannan P Samy; Allan D Kirk
Journal:  Nat Rev Nephrol       Date:  2016-02-29       Impact factor: 28.314

3.  Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs.

Authors:  Dan Li; Yufeng Li; Jessica A Hernandez; Rebecca Patenia; Tae Kon Kim; Jahan Khalili; Mark C Dougherty; Patrick J Hanley; Catherine M Bollard; Krishna V Komanduri; Patrick Hwu; Richard E Champlin; Laszlo G Radvanyi; Jeffrey J Molldrem; Qing Ma
Journal:  J Immunother       Date:  2010 Nov-Dec       Impact factor: 4.456

4.  The impact of lymphocytosis and CD4/CD8 ratio on the anti-JCV antibody index and clinical data in patients treated with natalizumab.

Authors:  Jan Kolcava; Monika Hulova; Lucie Rihova; Josef Bednarik; Pavel Stourac
Journal:  Neurol Sci       Date:  2020-11-17       Impact factor: 3.307

Review 5.  The evolving art of hematopoietic stem cell transplantation: translational research in post-transplant immune reconstitution and immunosuppression.

Authors:  Krishna V Komanduri; Eric D Wieder; Cara L Benjamin; Robert B Levy
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

6.  Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.

Authors:  Thomas F Benkert; Lena Dietz; Elena M Hartmann; Ellen Leich; Andreas Rosenwald; Edgar Serfling; Mathias Buttmann; Friederike Berberich-Siebelt
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.